GT Biopharma (GTBP) Cash Flow: Operating & Free Cash Flow

GT Biopharma Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for GT Biopharma, Inc. (GTBP) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Mar 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Operating Activities
Net Income	-28.35	-13.16	-7.60	-20.88	-58.01	-28.30	-28.30	-38.65	-259.19	-143.25
Depreciation & Amortization	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.01	0.00
Deferred Income Tax	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	228.52	4.91
Stock Based Compensation	0.43	0.23	2.20	7.65	33.93	0.27	0.27	5.31	9.70	130.12
Change in Working Capital	-0.92	0.78	1.83	-1.99	7.94	2.40	2.40	4.08	0.11	1.41
Change in Accounts Payable	-1.30	0.94	1.96	-2.03	7.08	-0.84	-0.84	3.15	0.14	1.41
Change in Other Working Capital	17.32	-0.16	-0.14	0.13	0.72	3.24	3.24	0.92	-0.03	1.41
Other Operating Activities	17.32	-0.75	-5.28	0.13	0.72	18.36	17.98	25.60	10.18	1.37
Net Cash from Operating Activities	-12.91	-12.90	-8.85	-15.22	-15.61	-7.26	-7.26	-3.66	-10.68	-5.43
Investing Activities
Capital Expenditures	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	-0.04	0.00
Purchases of Investments	0.00	12.89	-2.01	12.15	-23.04	0.00	-	0.00	0.00	0.00
Sales/Maturities of Investments	0.00	12.89	-2.01	12.15	-23.04	0.00	-	0.00	0.00	0.00
Other Investing Activities	0.00	0.00	-2.01	-12.15	0.00	0.00	-	0.20	0.00	0.00
Net Cash from Investing Activities	0.00	12.89	-2.01	12.15	-23.04	0.00	-	0.20	-0.04	0.00
Financing Activities
Debt Repayment	0.00	0.00	0.00	0.00	1.21	12.53	-	3.43	10.73	5.99
Common Stock Issued	16.00	2.98	6.27	0.00	24.68	0.00	-	0.00	0.00	0.00
Common Stock Repurchased	0.00	0.00	0.00	-0.22	0.00	0.00	-	0.00	0.00	0.00
Dividends Paid	-0.23	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00
Other Financing Activities	0.00	0.00	0.00	0.00	16.43	0.00	-	0.00	-0.53	0.00
Net Cash from Financing Activities	15.78	2.98	6.27	-0.22	42.32	12.53	12.53	3.43	10.20	5.99
Summary
Net Change in Cash	2.86	2.97	-4.59	-3.30	3.67	5.27	5.27	-0.03	-0.52	0.56
Cash at Beginning of Period	4.04	1.08	5.67	8.97	5.30	0.03	-	0.06	0.58	0.02
Cash at End of Period	6.91	4.04	1.08	5.67	8.97	5.30	-	0.03	0.06	0.58
Free Cash Flow	-12.91	-12.90	-8.85	-15.22	-15.61	-7.26	-7.26	-3.66	-10.71	-5.43
Supplemental Disclosures
Interest Paid	-	-	0.21	-	-	-	-	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About GT Biopharma Cash Flow

What is GT Biopharma's free cash flow?

GT Biopharma had negative free cash flow of $12.91M in fiscal 2025 (fiscal year ended Dec 31, 2025).

Does GT Biopharma pay dividends or buy back shares?

Yes. In fiscal 2025 GT Biopharma returned $229.00K in dividends to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition